Skip to main content
< Back to news
EIT Health Spain had received a total of 46 proposals, and these were winnowed down to 10 finalists, who participated in the pitch (Photo: EIT Health Spain).
 19.06.2017

Five Spanish start-ups pitch to win €50k in Headstart funding

Following a 26 May pitch contest at the Barcelona Science Park, five start-ups were selected to receive a total of €50 000 in funding each in the EIT Health Spain Headstart 2017 competition, a financial aid line launched by EIT Health as a part of the Accelerator Programme. Headstart funding is open to companies clearly-market oriented for the development of business ideas, and health products and services.

 

When the Headstart 2017 call closed, EIT Health Spain had received a total of 46 proposals, and these were winnowed down to 10 finalists, who participated in the pitch. The five winners are: Onalabs Inno Hub, 2Eyes Vision i Rethink Medical and two companies based at the Barcelona Science Park: Aelix Therapeutics and AVX Pharma.

Aelix Therapeutics is a biotechnology company focused on the development of a therapeutic HIV vaccine to be used as part of a cure/eradication strategy. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field. A phase II proof-of-concept clinical trial using the HTI immunogen its main product) as a therapeutic vaccine in people with HIV infection is foreseen to be completed by 2020. 

AVX Pharma is a clinical-stage Spanish biotech ophthalmology company founded in 2013 in Alicante and with offices in Barcelona Science Park, focused on developing novel therapies for Dry Eye Syndrome based on Prof. Carlos Belmonte research on the role of temperature-sensitive neurons in tear film regulation at the Alicante Neurosciences Institute. AVX Pharma lead product candidate AVX-012, a Small Molecule with a new Mechanism of Action, is in clinical development for Dry Eye Syndrome.
 

Related news [+]